The prevalence and associated factors of infusion-related reactions of the first full dose (600 mg) ocrelizumab instead of two doses apartN. Abbasi,F. Ghadiri, M. A. Sahraian,M. A. Nahayati,A. Naser Moghadasi,H. Ghalyanchi Langroodi,M. Poursadeghfard,S. Hosseini,H. Heidari,S. M. Baghbanian,H. Kamali, Z. Ameli,S. Shahmohammadi,S. NavardiMULTIPLE SCLEROSIS JOURNAL（2022）引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
